Anteris Technologies Global Corp. reported continued operating losses as it advances development of its DurAVR® transcatheter heart valve system and global pivotal Trial. Net sales from legacy tissue products were modest at $1.5 million for the six months ended June 30 2026, up 28% year over year, while the business remains primarily R&D-focused.
